Antibodies to human T-cell leukemia virus membrane antigens (HTLV-MA) in hemophiliacs. NLM AIDSLINE Important note: Information in this article was accurate in 1983. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Antibodies to human T-cell leukemia virus membrane antigens (HTLV-MA) in hemophiliacs.

Science. 1983 Sep 9;221(4615):1061-4. Unique Identifier : AIDSLINE MED/83275765
Essex M; McLane MF; Lee TH; Tachibana N; Mullins JI; Kreiss J; Kasper CK; Poon MC; Landay A; Stein SF; Francis DP; Cabradilla C; Lawrence DN; Evatt BL

Abstract: Along with homosexual men, Haitians, and intravenous drug abusers, hemophiliacs are at high risk of contracting acquired immunodeficiency syndrome (AIDS). An earlier study revealed that 36 percent of a group of the AIDS patients had antibodies to cell membrane antigens associated with the human T-cell leukemia virus (HTLV-MA), whereas only 1.2 percent of matched asymptomatic homosexual controls had these antibodies. In the present experiments, serum samples from 172 asymptomatic hemophiliacs were examined for the presence of antibodies to HTLV-MA. Such antibodies were detected in 5 to 19 percent of the hemophiliacs examined from four geographical locations, but in only 1 percent or less of laboratory workers, normal blood donors, donors on hemodialysis, or donors with chronic active hepatitis.
Keywords: Antibodies, Viral/*ANALYSIS Antigens, Surface/IMMUNOLOGY Antigens, Viral/*IMMUNOLOGY Comparative Study Hemophilia/IMMUNOLOGY/*MICROBIOLOGY Human Leukemia/*MICROBIOLOGY Retroviridae/*IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. *T-Lymphocytes JOURNAL ARTICLE

KWDantibodies,viral/KWDanalysisantigens,surface/immunologyantigens,viral/KWDimmunologycomparativestudyhemophilia/immunology/KWDmicrobiologyhumanleukemia/KWDmicrobiologyretroviridae/KWDimmunologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDs
831130
M83B0027

Copyright © 1983 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1983. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1983. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .